{
  "docId": "019de076-5473-7242-b1c4-ab6acd3f6564",
  "docSlug": "198a0f3704f292567efe1a435af44ee8",
  "documentTitle": "MAIA Biotechnology | Investor Presentation Deck | 39 slides",
  "authorId": "maia-biotechnology",
  "authorName": "MAIA Biotechnology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 39,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 20,
  "notes": "The slide presents two line charts showing tumor volume reduction over time for different treatment regimens in SCLC and HCC models.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-5473-7242-b1c4-ab6acd3f6564/28",
  "deckHref": "/decks/019de076-5473-7242-b1c4-ab6acd3f6564",
  "deckJsonHref": "/decks/019de076-5473-7242-b1c4-ab6acd3f6564.json",
  "deckAnchorHref": "/decks/019de076-5473-7242-b1c4-ab6acd3f6564#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "chart",
      "text": "SCLC tumor volume over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5dba2146-bdc4-494c-a021-6f8f2cefe5ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.55,
        "y": 0.15
      },
      "kind": "chart",
      "text": "HCC tumor volume over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ab28811-f64a-41fa-af3b-feb53df70754",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.52,
        "y": 0.65
      },
      "kind": "list",
      "text": "THIO is highly synergistic and effective in combination with anti-PD-L1 agent Atezolizumab and Ionizing Radiation (IR 10Gy) in HCC53N Hepatocellular Carcinoma. Treatment with THIO in combination with IR and Atezolizumab results in a complete regression of aggressive HCC tumors. The combination of IR and Atezolizumab is just partially efficacious.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4323a548-a7e2-4cf6-bc9a-ec76d476a951",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "THIO is synergistic with anti-PD-1 agent Pembrolizumab in Small Cell Lung Carcinoma (H2081) in vivo in humanized murine cancer model. Treatment with THIO followed by Pembrolizumab results in highly potent anticancer effect, as compared to Pembrolizumab alone. THIO converts immunologically “cold non-responsive” SCLC tumor into “hot and responsive” to Pembrolizumab.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb10c218-eb3c-42f8-b498-bb7e9cc7ba4a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "SCLC & HCC – ORPHAN DRUG DESIGNATION",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb4fbe27-f0b1-4583-a7a8-dd015c1b1fd3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 31,
      "from": 23,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "6627e548-b2f5-4984-b84a-467b48946446",
      "evidence": "The document presents an overview of MAIA Biotechnology's clinical trials and traction, highlighting its potential for quick wins and big bets.",
      "position": 1,
      "objective": "Can MAIA Biotechnology deliver quick wins and big bets in cancer treatment?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}